FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2941653074> ?p ?o ?g. }

• W2941653074 endingPage "e024467" @default.
• W2941653074 startingPage "e024467" @default.
• W2941653074 abstract "Chemotherapy-induced peripheral neuropathy (CIPN) is a prevalent and clinically meaningful side effect of cancer treatment. CIPN is induced by neurotoxic agents, causing severe sensory and/or motor deficits, resulting in disability and poor recovery, reducing patients' quality of life and limiting medical therapy. To date, effective treatment options are lacking. Whole-body vibration (WBV) training can attenuate motor and sensory deficits. We are conducting a two-armed, multicentre, assessor-blinded, randomised controlled trial, to investigate the effects of WBV on relevant symptoms of CIPN and determine the training characteristics.In this ongoing study, 44 patients who have completed therapy in the past 3 months, with a neurologically confirmed CIPN are assessed before and after a 12-week intervention and follow-up. The intervention group receives WBV twice a week. Exercises are individually tailored according to the initially determined optimal neuromuscular response. The control group receives care as usual.Primary endpoint is the patient reported reduction of CIPN-related symptoms (Functional Assessment of Cancer Therapy/Gynaecology Oncology Group-Neurotoxicity). Secondary endpoints are compound muscle action potentials, distal motor latency, conduction velocity, F-waves from the tibial and peroneal nerve, antidromic sensory nerve conduction studies of the sural nerve, normalised electromyographic activity, peripheral deep sensitivity, proprioception, balance, pain, the feasibility of training settings, quality of life and the level of physical activity.The study was approved by both responsible ethics committees. (1) Our results may contribute to a better understanding of the effects of WBV on motor and sensory functions and (2) may provide information whether WBV at the most effective setting, is feasible for neuropathic patients. (3) Our results may also contribute to improve supportive care in oncology, thereby enhancing quality of life and enabling the optimal medical therapy. All results will be published in international peer-reviewed journals as well as a manual for clinical practice.NCT03032718." @default.
• W2941653074 created "2019-05-03" @default.
• W2941653074 creator A5001881012 @default.
• W2941653074 creator A5010245587 @default.
• W2941653074 creator A5011268087 @default.
• W2941653074 creator A5015896502 @default.
• W2941653074 creator A5017999109 @default.
• W2941653074 creator A5024183729 @default.
• W2941653074 creator A5045704441 @default.
• W2941653074 creator A5047819937 @default.
• W2941653074 creator A5056580877 @default.
• W2941653074 creator A5065643830 @default.
• W2941653074 creator A5070477073 @default.
• W2941653074 creator A5073277581 @default.
• W2941653074 creator A5078217254 @default.
• W2941653074 creator A5080891591 @default.
• W2941653074 date "2019-04-01" @default.
• W2941653074 modified "2023-10-17" @default.
• W2941653074 title "Individually tailored whole-body vibration training to reduce symptoms of chemotherapy-induced peripheral neuropathy: study protocol of a randomised controlled trial—VANISH" @default.
• W2941653074 cites W1134022289 @default.
• W2941653074 cites W1187265560 @default.
• W2941653074 cites W1775697053 @default.
• W2941653074 cites W1985920917 @default.
• W2941653074 cites W2000366267 @default.
• W2941653074 cites W2015619102 @default.
• W2941653074 cites W2017673766 @default.
• W2941653074 cites W2025651303 @default.
• W2941653074 cites W2037080775 @default.
• W2941653074 cites W2043405547 @default.
• W2941653074 cites W2058772031 @default.
• W2941653074 cites W2061842312 @default.
• W2941653074 cites W2062228543 @default.
• W2941653074 cites W2063700778 @default.
• W2941653074 cites W2071957083 @default.
• W2941653074 cites W2074276081 @default.
• W2941653074 cites W2074474208 @default.
• W2941653074 cites W2078660005 @default.
• W2941653074 cites W2080382070 @default.
• W2941653074 cites W2083668350 @default.
• W2941653074 cites W2086155638 @default.
• W2941653074 cites W2094554530 @default.
• W2941653074 cites W2096491215 @default.
• W2941653074 cites W2097502034 @default.
• W2941653074 cites W2107114700 @default.
• W2941653074 cites W2121538189 @default.
• W2941653074 cites W2124394452 @default.
• W2941653074 cites W2127661610 @default.
• W2941653074 cites W2131776506 @default.
• W2941653074 cites W2143293793 @default.
• W2941653074 cites W2149350769 @default.
• W2941653074 cites W2160610973 @default.
• W2941653074 cites W2165453261 @default.
• W2941653074 cites W2167571044 @default.
• W2941653074 cites W2269520932 @default.
• W2941653074 cites W2314111539 @default.
• W2941653074 cites W2529465285 @default.
• W2941653074 cites W2783534816 @default.
• W2941653074 cites W2884287273 @default.
• W2941653074 cites W2899242335 @default.
• W2941653074 cites W4253122746 @default.
• W2941653074 cites W4297914157 @default.
• W2941653074 doi "https://doi.org/10.1136/bmjopen-2018-024467" @default.
• W2941653074 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6501973" @default.
• W2941653074 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31023750" @default.
• W2941653074 hasPublicationYear "2019" @default.
• W2941653074 type Work @default.
• W2941653074 sameAs 2941653074 @default.
• W2941653074 citedByCount "5" @default.
• W2941653074 countsByYear W29416530742020 @default.
• W2941653074 countsByYear W29416530742021 @default.
• W2941653074 countsByYear W29416530742022 @default.
• W2941653074 crossrefType "journal-article" @default.
• W2941653074 hasAuthorship W2941653074A5001881012 @default.
• W2941653074 hasAuthorship W2941653074A5010245587 @default.
• W2941653074 hasAuthorship W2941653074A5011268087 @default.
• W2941653074 hasAuthorship W2941653074A5015896502 @default.
• W2941653074 hasAuthorship W2941653074A5017999109 @default.
• W2941653074 hasAuthorship W2941653074A5024183729 @default.
• W2941653074 hasAuthorship W2941653074A5045704441 @default.
• W2941653074 hasAuthorship W2941653074A5047819937 @default.
• W2941653074 hasAuthorship W2941653074A5056580877 @default.
• W2941653074 hasAuthorship W2941653074A5065643830 @default.
• W2941653074 hasAuthorship W2941653074A5070477073 @default.
• W2941653074 hasAuthorship W2941653074A5073277581 @default.
• W2941653074 hasAuthorship W2941653074A5078217254 @default.
• W2941653074 hasAuthorship W2941653074A5080891591 @default.
• W2941653074 hasBestOaLocation W29416530741 @default.
• W2941653074 hasConcept C126322002 @default.
• W2941653074 hasConcept C134018914 @default.
• W2941653074 hasConcept C159110408 @default.
• W2941653074 hasConcept C168563851 @default.
• W2941653074 hasConcept C171790689 @default.
• W2941653074 hasConcept C1862650 @default.
• W2941653074 hasConcept C2778818304 @default.
• W2941653074 hasConcept C2779289229 @default.
• W2941653074 hasConcept C2779901536 @default.
• W2941653074 hasConcept C2779951463 @default.
• W2941653074 hasConcept C555293320 @default.

• next